A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

CONCLUSIONS: We observed a low response rate to zanidatamab in recurrent HER2+ endometrial carcinoma/carcinosarcoma, which may be driven by downregulation of HER2 expression. Repeat HER2 testing should be considered prior to second-line HER2-directed therapy.CLINICALTRIALS: govidentifier: NCT04513665.PMID:38262242 | DOI:10.1016/j.ygyno.2023.12.028

Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Melissa Lumish M Herman Chui Qin Zhou Alexia Iasonos Debra Sarasohn Seth Cohen Claire Friedman Rachel Grisham Jason Konner Chrisann Kyi Maria Rubinstein Tiffany Troso-Sandoval Carol Aghajanian Vicky Makker Source Type: research